The FDA is clarifying when one rigorous pivotal trial supported by confirmatory evidence may establish a drug’s effectiveness. The approach could shorten development in rare diseases and precision medicine, but it does not turn small, uncontrolled or statistically fragile studies into approval-ready evidence.
Amgen’s Tepezza is facing a broader thyroid eye disease treatment landscape after Viridian Therapeutics’ Lumvoa became another approved option, shifting attention toward how physicians may weigh evidence, safety, treatment burden and patient fit. Dr. Raymond Douglas, MD, PhD, who served as principal investigator in the international Tepezza trials that supported its United States Food and
ICON and Anthropic will build Claude-powered clinical trial tools inside Orbis, targeting site selection, enrolment risk and protocol design.
Regenative Labs reports lower pain and WOMAC scores after paraspinal allograft use, but controlled trials and regulatory clarity remain essential.
Bayer-backed research says self-care can ease health-system strain, but only with safeguards, affordable access and clear referral pathways.
OneLegacy is expanding OrganOx metra liver perfusion access across Southern California, testing whether a shared hub can increase transplant capacity.
Avacta’s next AVA6103 data will test sustained exatecan release in cancer patients. Read what the FOCUS-01 results could mean for its platform.
Read how Repligen’s $1.5 billion BioLife deal could expand its cell therapy manufacturing reach, recurring revenue and global customer base.
AstraZeneca is funding a five-year YMCA cancer initiative that will begin in 75 communities, but its impact will depend on whether education leads to completed screenings, clinical referrals and sustained survivor support.
Avacta Group PLC has agreed a potential full-approval pathway for faridoxorubicin with the United States Food and Drug Administration, while new clinical analyses suggest the drug may work even in tumours with very low FAP expression. The pivotal opportunity is becoming clearer, but Avacta still needs mature progression-free survival data, a development partner and evidence